Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: FASEB J. 2021 Apr;35(4):e21437. doi: 10.1096/fj.202002755R

Figure 2. CaMKIIδ is upregulated by Interleukin-6 (IL-6).

Figure 2.

A. RNAseq data of CAMK2A, CAMK2B, CAMK2D, AND CAMK2G following treatment with DMSO, 200 ng/mL IL-6 and 100 ng/mL sIL6r for three hours, or IL-6/sIL-6r with 30-minute pretreatment with 2 μM ruxolitinib. Statistical analyses performed by Genewiz. B. qPCR analysis of CAMK2D and CAMK2G following treatment with 200 ng/mL IL-6 and 100 ng/mL sIL6r for three hours, normalized to GAPDH, n = 4. Student’s t-test, (*) p <0.05 C. Confluent HUVEC monolayers were pretreated with Actinomycin D (10 μg/ mL) for 30 minutes before treatment with IL-6/sIL-6r for 3 hours. qPCR analysis of CAMK2D normalized to GAPDH, n = 3. Two-Way ANOVA, (*) p < 0.05. D. Custom CaMKII antibody immunoblot to CaMKIIγ, CaMKIIδ2, and CaMKIIδ6 normalized to ACTB. Confluent HUVEC treated with IL-6/sIL-6r for 24h. n = 3. Student’s t-test, (*) p <0.05.